ethyl 2-[(6-methylpyridin-3-yl)oxy]acetate | 24015-97-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 2-[(6-methylpyridin-3-yl)oxy]acetate
• 英文别名: ethyl 2[(6-methylpyridin-3-yl)oxy]acetate；ethyl [(6-methylpyridin-3-yl)oxy]acetate；(6-methyl-pyridin-3-yloxy)-acetic acid ethyl ester；ethyl (6-methyl-pyridin-3-yl)oxyacetate；ethyl 6-methyl-pyridin-3-yloxyacetate；ethyl (6-methyl-3-pyridyl)oxyacetate；Ethyl 6-methyl-3-pyridyloxyacetate；ethyl 2-(6-methylpyridin-3-yl)oxyacetate
• CAS: 24015-97-2
• 化学式: C₁₀H₁₃NO₃
• 分子量: 195.218
• InChiKey: SLQPGPDBDCSQMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-[(6-methylpyridin-3-yl)oxy]acetate 在 4-甲基苯磺酸吡啶 lithium aluminium tetrahydride 、 水 、 lithium chloride 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 77.0h， 生成 1-[4-(dodecyloxy)phenyl]-2-[5-(2-hydroxyethoxy)pyridin-2-yl]ethan-1-one
  参考文献：
  名称：

  (−)-Isocamphoric Acid Building Block for Chiral Liquid Crystals

  摘要：

  DOI：

  10.1002/(sici)1522-2675(19991006)82:10<1707::aid-hlca1707>3.0.co;2-k
• 作为产物：
  描述：

  3-羟基-6-甲基吡啶 、 溴乙酸乙酯 在 盐酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 生成 ethyl 2-[(6-methylpyridin-3-yl)oxy]acetate
  参考文献：
  名称：

  2-[2-(2-Aminoalkyl-4-thiazolylmethylthio)alkyl]-amino-5-substituted-4-pyr

  摘要：

  2-[2-(2-氨基烷基-4-噻唑甲硫基)-烷基]氨基-5-芳基取代的烷基-4-嘧啶酮及相关化合物，H2受体拮抗剂，在哺乳动物中抑制胃酸分泌方面有用。

  公开号：

  US04468399A1

文献信息

• HIV protease inhibiting compounds
  申请人：DeGoey A. David

  公开号：US20050131017A1

  公开（公告）日：2005-06-16

  A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

  公开了一种公式的化合物作为HIV蛋白酶抑制剂。还公开了用于抑制HIV感染的方法和组合物。
• [EN] MODULATORS OF THE INTEGRATED STRESS PATHWAY<br/>[FR] MODULATEURS DE LA VOIE DE RÉPONSE INTÉGRÉE AU STRESS
  申请人：CALICO LIFE SCIENCES LLC

  公开号：WO2019090069A1

  公开（公告）日：2019-05-09

  Provided herein are compounds, compositions, and methods useful for the modulation of elF2B, for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

  本文提供了用于调节elF2B、调节综合应激反应（ISR）以及治疗相关疾病、疾病和症状的化合物、组合物和方法。
• 2-[2-(2-Aminoalkyl-4-thiazolylmethylthio)alkyl]-amino-5-substituted-4-pyr
  申请人：Eli Lilly and Company

  公开号：US04468399A1

  公开（公告）日：1984-08-28

  2-[2-(2-aminoalkyl-4-thiazolylmethylthio)-alkylene]amino-5-aromatic-substit uted alkylene-4-pyrimidones and related compounds, H.sub.2 receptor antagonists, useful in inhibiting gastric acid secretion in mammals.

  2-[2-(2-氨基烷基-4-噻唑甲硫基)-烷基]氨基-5-芳基取代的烷基-4-嘧啶酮及相关化合物，H2受体拮抗剂，在哺乳动物中抑制胃酸分泌方面有用。
• [EN] SUBSTITUTED AMIDES<br/>[FR] AMIDES SUBSTITUES
  申请人：MERCK & CO INC

  公开号：WO2003077847A2

  公开（公告）日：2003-09-25

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可作为中枢作用药物，用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化和格林-巴利综合征）以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍，以及哮喘、便秘、慢性肠假性梗阻和肝硬化的治疗。
• Substituted amides
  申请人：——

  公开号：US20040058820A1

  公开（公告）日：2004-03-25

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可作为中枢作用药物用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎症性疾病，包括多发性硬化症和格林-巴利综合症以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、应激、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍，以及哮喘、便秘、慢性肠假性梗阻和肝硬化的治疗。